Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
KDA Group (KDA.V) on Thursday said an evaluation of its digital platform Medherize in breast-cancer
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrate
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the voting results of the annual general meeting of shareholders (the "Meeting") held on April 29, 2026, in Quebec.
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the appointment of Mr. Martin Kirouac as Chief Technology Officer of Groupe Technologique KDA Inc. ("GTK"), a wholly-owned subsidiary of KDA. This appointment is effective immediately.
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, announces the closing of the transaction pursuant to which the Corporation acquired the twenty percent (20%) minority interest in the issued and outstanding shares of its subsidiary Groupe Technologique KDA Inc. ("GTK") held by ERxpert Inc. ("ERxpert") in exchange for thirty-five million (35,000,000) common shares of KDA's share capital issued to ERxpert (the "Tra
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.